Rosuzet (Hanmi, Rosuvastatin-Ezetimibe), a blockbuster drug with annual prescriptions of ₩99.1 billion, expects to add a new dose.

Rosuzet is currently licensed for three doses, and the new dose is known to contain unlicensed doses in Korea. According to industry sources on the 12th, Hanmi recently applied for a new dose of Rosuzet to the MFDS.

Rosuzet is a combination drug that combines Rosuvastatin and Ezetimibe, an ingredient for treating hyperlipidemia, containing Ezetimibe 10 mg and three different doses of Rosuvastatin. Specifically, there are 3 items including Ezetimibe-Rosuvastatin 10/10mg, 10/20mg, and 10/5mg.


Currently, Rosuvastatin 5mg, 10mg, and 20mg a